Stock Events

Rhythm Pharmaceuticals 

M$733.48
0
+M$0+0% Tuesday 15:29

Statistics

Day High
733.48
Day Low
733.48
52W High
733.48
52W Low
308
Volume
12,400
Avg. Volume
118
Mkt Cap
36.54B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-1
-0.9
-0.79
-0.69
Expected EPS
-0.69
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RYTM.MX. It's not an investment recommendation.

About

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. David P. Meeker M.D.
Employees
140
Country
United States
ISIN
US76243J1051
WKN
000A2H5A0

Listings